Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122526552 | 12252655 | 2 | F | 20160822 | 20160411 | 20160829 | PER | US-PFIZER INC-2016202374 | PFIZER | 66.00 | YR | F | Y | 66.00000 | KG | 20160829 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122526552 | 12252655 | 1 | PS | VFEND | VORICONAZOLE | 1 | Oral | 200 MG, 2X/DAY | F10201930 | 21266 | 200 | MG | FILM-COATED TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122526552 | 12252655 | 1 | Aspergillus infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122526552 | 12252655 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122526552 | 12252655 | Head injury | |
| 122526552 | 12252655 | Memory impairment | |
| 122526552 | 12252655 | Pneumonia | |
| 122526552 | 12252655 | Stevens-Johnson syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122526552 | 12252655 | 1 | 20160304 | 20160404 | 0 |